Yargesa

Adult Dosing .

Dosage forms:  CAP: 100 mg

Gaucher disease, type 1

[100 mg PO tid]

Info: for patients with mild-moderate disease; may decr. dose to 100 mg PO qd-bid if not tolerated

Niemann-Pick disease, type C (off-label)

[200 mg PO tid]

Info: for patients with progressive neurological symptoms; may decr. dose if not tolerated

renal dosing

[Gaucher disease, type 1]

CrCl 50-70: 100 mg bid; CrCl 30-49: 100 mg qd; CrCl <30: avoid use

HD/PD: not defined

[Niemann-Pick disease, type C]

CrCl 50-70: 200 mg bid; CrCl 30-49: 100 mg bid; CrCl <30: avoid use

HD/PD: not defined

hepatic dosing

[not defined]

Peds Dosing .

Dosage forms:  CAP: 100 mg

Niemann-Pick disease, type C (off-label)

[4-11 yo, BSA <0.47 m^2]

Dose: 100 mg PO qd; Info: for patients with progressive neurological symptoms; may decr. dose if not tolerated

[4-11 yo, BSA 0.48-0.73 m^2]

Dose: 100 mg PO bid; Info: for patients with progressive neurological symptoms; may decr. dose if not tolerated

[4-11 yo, BSA 0.74-0.88 m^2]

Dose: 100 mg PO tid; Info: for patients with progressive neurological symptoms; may decr. dose if not tolerated

[4-11 yo, BSA 0.89-1.25 m^2]

Dose: 200 mg PO bid; Info: for patients with progressive neurological symptoms; may decr. dose if not tolerated

[4-11 yo, BSA >1.26 m^2]

Dose: 200 mg PO tid; Info: for patients with progressive neurological symptoms; may decr. dose if not tolerated

[12 yo and older]

Dose: 200 mg PO tid; Info: for patients with progressive neurological symptoms; may decr. dose if not tolerated

renal dosing

[<12 yo]

CrCl 50-70: consider decr. usual frequency adjusted for BSA; CrCl 30-49: consider decr. usual dose and frequency adjusted for BSA; CrCl <30: avoid use

HD/PD: not defined

[12 yo and older]

CrCl 50-70: 200 mg bid; CrCl 30-49: 100 mg bid; CrCl <30: avoid use

HD/PD: not defined

hepatic dosing

[not defined]